After Gilead Sciences, Inc.’s fourth quarter sales came in lower than expected and the company issued 2024 guidance that analysts found unexciting, the drug maker is pinning its hopes on a number of catalysts in virology and oncology that it anticipates throughout the year.
The Foster City, CA-based drug maker announced its fourth quarter and full year 2023 earnings on 6 February, reporting Q4...